Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telisotuzumab adizutecan - AbbVie

Next Previous
Drug Profile

Telisotuzumab adizutecan - AbbVie

Alternative Names: ABBV-400; Temab-A

Latest Information Update: 23 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Adenocarcinoma; Solid tumours
  • No development reported Gastric cancer; Oesophageal cancer

Most Recent Events

  • 10 Dec 2025 Phase-II/III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Taiwan, Japan, Australia, Israel (IV) (NCT07155187)
  • 04 Dec 2025 Phase-II clinical trials in Solid tumours (In adolescents, In adults, In the elderly, Second-line therapy or greater, Metastatic disease, Late-stage disease) in South Korea, Japan, Israel, USA (IV) (NCT07196644)
  • 29 Sep 2025 AbbVie plans a phase II trial for Solid tumours (Late-stage disease, Metastatic disease, In adults, In adolescents) (Intravenous, infusion) (NCT07196644)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top